Citable filing context
ALNY's research view summarizes recent SEC filing context, starting with earnings from Jul 30, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 30, 2026 | earnings | Alnylam Pharmaceuticals reported Q2 2026 net product revenues of $1.172 billion and revised its full-year TTR revenue guidance. |
| May 27, 2026 | management_change | Alnylam Pharmaceuticals expanded its Board to eleven members and elected Benjamin F. Cravatt as a director. |
| Apr 30, 2026 | earnings | Alnylam reported Q1 2026 net product revenues of $1.036 billion, a 121% increase compared to Q1 2025. |
| Jul 30, 2026 | Guidance: net_revenues_from_collaborations_and_royalties | 575.00 to 625.00 |
| Jul 30, 2026 | Guidance: non_gaap_rd_and_sga_expenses | 2700.00 to 2800.00 |
| Jul 30, 2026 | Guidance: total_net_product_revenues | 4700.00 to 5100.00 |
| Jul 30, 2026 | mda_quarterly | Alnylam Pharmaceuticals has transitioned to a profitable commercial-stage company, reporting $1.29 billion in total revenue for the second quarter of 2026, a 67% increase year-over-year. Growth is primarily driven by AMVUTTRA, which saw significant adoption following its approval for ATTR-cardiomyopathy, offsetting declining revenues from ONPATTRO. Rare disease products GIVLAARI and OXLUMO also contributed steady growth. The company is executing its "Alnylam 2030" strategy, focusing on expanding its RNAi platform across 10 tissue types. Key pipeline developments include the late-stage nucresiran program for ATTR amyloidosis, where enrollment for the TRITON-CM trial was expanded to 1,750 patients, and the zilebesiran hypertension program, now in a Phase 3 cardiovascular outcomes trial (ZENITH) under a strategic collaboration with Roche. Additionally, Regeneron has filed for regulatory approval of cemdisiran for myasthenia gravis. Financial health is supported by robust product sales and collaboration milestones, though operating expenses remain high due to heavy investment in R&D and global commercial infrastructure. While the company maintains a $500 million revolving credit facility and sufficient liquidity for the next 12 months, profitability remains sensitive to tiered royalty obligations on AMVUTTRA and the inherent risks of clinical trial success and regulatory approval timelines. |
| Apr 30, 2026 | mda_quarterly | Alnylam achieved profitability in 2025, with Q1 2026 total revenues reaching $1.17 billion, a 96% increase year-over-year. Growth was primarily driven by AMVUTTRA, which generated $890 million in Q1 following regulatory approvals for ATTR cardiomyopathy (ATTR-CM) in the U.S. and EU. While AMVUTTRA drives top-line growth, tiered royalties paid to Sanofi—reaching up to 30% of net sales—have increased cost of goods sold to 20% of product revenues. To improve margins, Alnylam is advancing nucresiran, a next-generation TTR silencer in Phase 3 (TRITON-PN and TRITON-CM), which carries no royalty obligations. Other key pipeline catalysts include the Phase 3 ZENITH trial for zilebesiran in hypertension, partnered with Roche, and the NDA submission for cemdisiran in myasthenia gravis, partnered with Regeneron. The company is executing its "Alnylam 2030" strategy, targeting a 25%+ revenue CAGR and expansion into 10 tissue types. Recent financing activities include the issuance of $661.3 million in 0.00% convertible senior notes due 2028 and the repurchase of approximately $672 million of 2027 notes. A $500 million revolving credit facility provides additional liquidity to support ongoing R&D and commercial launches. |
Source: SEC EDGAR filing text and events; period Jul 30, 2026; filed Jul 30, 2026.
ALNY company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.